Table 1 Baseline clinical characteristics
All (n = 150) | LTC group (cholesterol ≤ 12.40 mmol/L, n = 77) | HTC group (cholesterol > 12.40 mmol/L, n = 73) | p | |
|---|---|---|---|---|
Baseline characteristics | ||||
Age (years) | 38.00 (31.00–44.00) | 36.00 (31.00–43.00) | 40.00 (33.00–45.00) | 0.047 |
Male | 118 (78.67%) | 66 (85.71%) | 52 (71.23%) | 0.049 |
BMI (kg/m2) | 26.15 (24.20–28.30) | 26.00 (24.80–28.40) | 26.40 (24.20–28.30) | 0.880 |
Hypertension | 23 (15.33%) | 10 (12.99%) | 13 (17.80%) | 0.553 |
Diabetes | 44 (29.33%) | 20 (25.97%) | 24 (32.88%) | 0.454 |
History of pancreatitis | 59 (39.33%) | 33 (45.21%) | 25 (34.25%) | 0.282 |
TG (mg/dL) | 1760.20 (1187.60–2534.30) | 1599.10 (1140.70–1981.40) | 2224.80 (1351.30–3291.20) | < 0.001 |
TC (mmol/L) | 12.28 (8.83–15.96) | |||
HDL-C (mmol/L) | 0.97 (0.59–2.86) | 0.97 (0.61–2.37) | 0.93 (0.58–4.23) | 0.347 |
LDL-C (mmol/L) | 2.86 (1.55–5.30) | 1.91 (1.18–3.31) | 4.50 (2.13–7.23) | < 0.001 |
Ca (mmol/L) | 2.17 (1.98–2.48) | 2.24 (2.05–2.48) | 2.11 (1.95–2.59) | 0.183 |
Amylase (U/L) | 202.00 (108.20–391.80) | 246.00 (110.00–373.00) | 182.00 (84.00–396.00) | 0.330 |
Lipase (U/L) | 627.80 (290.30–1513.20) | 588.00 (288.10–1496.00) | 637.00 (297.60–1592.00) | 0.867 |
Severity of hypertriglyceridemic pancreatitis | ||||
Balthazar CT grade | < 0.001 | |||
< D | 73 (48.67%) | 48 (62.33%) | 25 (34.25%) | |
≥ D | 77 (51.33%) | 29 (37.66%) | 48 (65.75%) | |
Organ function | 0.111 | |||
NO | 120 (80.00%) | 66 (85.71%) | 54 (73.97%) | |
YES | 30 (20.00%) | 11 (14.29%) | 19 (26.03%) | |
Ranson score | 0.396 | |||
< 3 | 130 (86.67%) | 69 (89.61%) | 61 (83.56%) | |
≥ 3 | 20 (13.33%) | 8 (10.39%) | 12 (16.44%) | |
APACHE II | 7.00 (5.00–9.00) | 7.00 (5.00–9.00) | 8.00 (6.00–10.00) | 0.036 |
Treatment | ||||
Insulin | 101 (67.33%) | 51 (66.23%) | 50 (68.49%) | 0.904 |
Heparin | 84 (56.00%) | 43 (55.84%) | 41 (56.16%) | 1 |
AP-associated death | 4 (2.67%) | 0 (0%) | 4 (5.48%) | 0.054 |